Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026
Rhea-AI Summary
Inotiv (NASDAQ: NOTV) will report fiscal 2026 first quarter results for the period ended December 31, 2025, on Monday, February 9, 2026, before the market opens.
The company will host a conference call the same day at 8:30 a.m. Eastern Time with domestic and international dial‑in access and a live webcast. An online replay will be available in the Investors section of Inotiv's website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, NOTV declined 6.83%, reflecting a notable negative market reaction. Argus tracked a trough of -24.1% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $16M at that time. Trading volume was elevated at 2.4x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NOTV was down 5.56% while close peers showed mixed moves: PRPO up 8.98%, BDSX up 5.85%, ADVB up 4.17%, PRPH down 8.05%. Scanner momentum only flagged ADVB moving down, suggesting stock-specific factors rather than a broad sector swing.
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 21 | Earnings date notice | Neutral | -3.9% | Announced timing of FY2025 Q4 and full-year results and conference call. |
Prior earnings-date conference announcements saw a negative price reaction despite neutral content.
Recent history for Inotiv shows that scheduling earnings-related conference calls has coincided with weakness. The prior conferences,earnings date announcement on Nov 21, 2025 about reporting FY2025 Q4 and full-year results led to a -3.89% move. Today’s notice similarly sets expectations for an earnings release and call, against a backdrop of shares already trading near a 52-week low and well below the 200-day MA.
Historical Comparison
The last earnings-date conference notice in Nov 2025 saw NOTV move -3.89%. Today’s similar earnings-date announcement fits a pattern where neutral scheduling news coincided with downside pressure.
The company continues a consistent cadence of pre-announcing earnings release dates and related conference calls, moving from FY2025 Q4 timing in Nov 2025 to the FY2026 Q1 date in Feb 2026.
Regulatory & Risk Context
Inotiv has an effective S-3 shelf filed on 2025-08-29, enabling future securities offerings, including an at-the-market program with up to 3.0% sales commission to Jefferies. The prospectus highlights an auditor’s going-concern explanatory paragraph and material weaknesses in internal controls, and warns of potential immediate dilution and variability of proceeds from any ATM activity.
Market Pulse Summary
The stock moved -6.8% in the session following this news. The decline reflects existing fragility, with shares already deeply below the 200-day MA and close to the 52-week low. Historically, the last earnings-date notice coincided with a -3.89% move, so renewed weakness around another scheduling release would fit that pattern. Ongoing concerns highlighted in the S-3 shelf, including going-concern language and dilution risk, could reinforce downside pressure.
AI-generated analysis. Not financial advice.
WEST LAFAYETTE, Ind., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2026 first quarter ended December 31, 2025, on Monday, February 9, 2026, before the stock market opens. The Company will host a conference call that same day at 8:30 a.m. Eastern Time to discuss the results.
Interested parties may participate in the call by dialing:
- 1-800-445-7795 (Domestic)
- 1-785-424-1699 (International)
- INOTIV (Conference ID)
The live conference call webcast will be accessible in the Investors section of the Company’s web site and directly via the following link:
https://viavid.webcasts.com/starthere.jsp?ei=1750994&tp_key=1585804d3b
For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv’s web site at: https://ir.inotiv.com/events-and-presentations/default.aspx
About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotiv.com/.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the Company’s ability to comply with covenants under its credit agreement, compliance with the Resolution and Plea Agreements with the U.S. Department of Justice and the expected impacts on the Company related to the compliance plan, compliance monitor, and the expected financial commitments, changes in the market and demand for the Company’s products and services, the Company's assessment of its cybersecurity incident, ongoing or potential impacts, and efforts of the Company related to the incident, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, claims and litigation against or involving the Company, its business and/or its industry, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
| Company Contact | Investor Relations | |
| Inotiv, Inc. | LifeSci Advisors | |
| Beth A. Taylor, Chief Financial Officer | Steve Halper | |
| (765) 497-8381 | (646) 876-6455 | |
| beth.taylor@inotiv.com | shalper@lifesciadvisors.com |
FAQ
When will Inotiv (NOTV) release its fiscal 2026 Q1 results?
What time is the Inotiv (NOTV) conference call for the February 9, 2026 earnings release?
How can investors join the Inotiv (NOTV) earnings call on February 9, 2026?
Where will the Inotiv (NOTV) live webcast and replay be available for the February 9, 2026 call?
Will Inotiv (NOTV) provide a replay of the February 9, 2026 conference call if I cannot listen live?
